Search

Your search keyword '"Kukreti, Vishal"' showing total 1,010 results
Start Over Author "Kukreti, Vishal"
1,010 results on '"Kukreti, Vishal"'

201. Treatment of relapsed/refractory multiple myeloma with weekly cyclophosphamide plus bortezomib plus prednisone or dexamethasone (CyBor-P/D): Updated experience at Princess Margaret Cancer Centre (PMCC).

Author

Reece, Donna Ellen, primary, Trieu, Young, additional, Masih-Khan, Esther, additional, Chen, Christine, additional, Kukreti, Vishal, additional, Rodriguez, Giovanni Piza, additional, Tiedemann, Rodger Edwin, additional, and Trudel, Suzanne, additional

Published
2014
Full Text
View/download PDF

205. CrebbpMutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation

Author

Hershenfeld, Samantha A, Shelton, Victoria, Bakhtiari, Mehran, Calvente, Lourdes, Lajkosz, Katherine, Isaev, Keren, Silva, Anjali, Liu, Ting, Brodtkorb, Marianne, d'Amore, Francesco Annibale, Ludvigsen, Maja, Madsen, Charlotte, Hamilton-Dutoit, Stephen, Gandhi, Maher, Tobin, Joshua W.D., Baetz, Tara, LeBrun, David, Johnson, Nathalie A., Mungall, Andrew J., Crump, Michael, Delabie, Jan, Gospodarowicz, Mary, Hodgson, David, Hong, Michael, Kukreti, Vishal, Kuruvilla, John, Prica, Anca, Tremblay-Lemay, Rosemarie, Tsang, Richard, and Kridel, Robert

Published
2022
Full Text
View/download PDF

206. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question

Author

Hicks, Lisa K., primary, Bering, Harriet, additional, Carson, Kenneth R., additional, Kleinerman, Judith, additional, Kukreti, Vishal, additional, Ma, Alice, additional, Mueller, Brigitta U., additional, O'Brien, Sarah H., additional, Pasquini, Marcelo, additional, Sarode, Ravindra, additional, Solberg, Lawrence, additional, Haynes, Adam E., additional, and Crowther, Mark A., additional

Published
2013
Full Text
View/download PDF

207. Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution

Author

Jimenez‐Zepeda, Victor H., primary, Franke, Norman, additional, Reece, Donna E., additional, Trudel, Suzanne, additional, Chen, Christine, additional, Delgado, Diego H., additional, Winter, Andrew, additional, Mikhael, Joseph R., additional, Tiedemann, Rodger, additional, and Kukreti, Vishal, additional

Published
2013
Full Text
View/download PDF

219. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.

Author

Kotchetkov, Rouslan, Masih‐Khan, Esther, Chu, Chia‐Min, Atenafu, Eshetu G., Chen, Christine, Kukreti, Vishal, Trudel, Suzanne, Tiedemann, Rodger, and Reece, Donna E.

Subjects
DEXAMETHASONE, MULTIPLE myeloma, ACUTE myeloid leukemia, CANCER relapse, MULTIVARIABLE testing, PATIENTS
Abstract

Lenalidomide in combination with dexamethasone (Len-dex) represents a highly effective treatment in relapsed/refractory multiple myeloma ( RRMM) patients. However, an increased risk of secondary primary malignancies ( SPMs), including myelodysplastic syndrome ( MDS) and acute myelogenous leukemia ( AML) has been described in patients receiving lenalidomide. In order to assess the incidence and features of this complication, we reviewed 195 patients with RRMM treated with Len-dex at our institution. The median follow-up time from diagnosis of MM was 73 months (10-234 months) and from initiation of Len-dex was 19 months (1-104 months). The median duration of Len-dex for all patients was 7.8 months (range 1-90 months). The incidence rate ( IR) for all SPMs from start of Len-dex was 2.37 per 100 patient-years, which reflected an IR of 1.29 for MDS/ AML and 1.08 for nonhematologic malignancies ( NHM). MDS was the most common SPM noted. The cumulative IR of SPM at 5 years was 1.54% from the time of MM diagnosis and 5.24% from starting Len-dex. Multivariable cumulative incidence of SPM analysis identified older age ( P = 0.005) and prior number of regimens ( P = 0.026) as adverse risk factors. We found more concomitant G- CSF use ( P = 0.029) in patients with MDS/ AML, however, causal association is not clear. The progression-free survival after Len-dex was the longest for patients in MDS/ AML group, and the 5-year overall survival did not differ among groups. Although the rate of SPM was relatively low with Len-dex, concomitant G- CSF should be used judiciously and patients receiving this regimen should be observed for the development of this complication. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

220. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.

Author

Gupta, Neeraj, Hanley, Michael J., Harvey, R. Donald, Badros, Ashraf, Lipe, Brea, Kukreti, Vishal, Berdeja, Jesus, Yang, Huyuan, Hui, Ai‐Min, Qian, Mark, Zhang, Xiaoquan, Venkatakrishnan, Karthik, and Chari, Ajai

Subjects
MULTIPLE myeloma treatment, KIDNEY disease treatments, PROTEASOME inhibitors, PHARMACOKINETICS, HEMODIALYSIS, THERAPEUTICS
Abstract

Renal impairment ( RI) is a major complication of multiple myeloma ( MM). This study aimed to characterize the single-dose pharmacokinetics ( PK) of the oral proteasome inhibitor, ixazomib, in cancer patients with normal renal function [creatinine clearance (CrCl) ≥90 ml/min; n = 20), severe RI (CrCl <30 ml/min; n = 14), or end-stage renal disease requiring haemodialysis ( ESRD; n = 7). PK and adverse events ( AEs) were assessed after a single 3 mg dose of ixazomib. Ixazomib was highly bound to plasma proteins (~99%) in all renal function groups. Unbound and total systemic exposures of ixazomib were 38% and 39% higher, respectively, in severe RI/ ESRD patients versus patients with normal renal function. Total ixazomib concentrations were similar in pre- and post-dialyser samples collected from ESRD patients; therefore, ixazomib can be administered without regard to haemodialysis timing. Except for anaemia, the incidence of the most common AEs was generally similar across groups, but grade 3 and 4 AEs were more frequent in the severe RI/ ESRD groups versus the normal group (79%/57% vs. 45%), as were serious AEs (43%/43% vs. 15%). The PK and safety results support a reduced ixazomib dose of 3 mg in patients with severe RI/ ESRD. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

222. A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.

Author

Hay, Annette E., Murugesan, Alli, DiPasquale, Ashley M., Kouroukis, Tom, Sandhu, Irwindeep, Kukreti, Vishal, Bahlis, Nizar J., Lategan, Johan, Reece, Donna E., Lyons, John F., Sederias, Joana, Xu, Hao, Powers, Jean, Seymour, Lesley K., and Reiman, Tony

Subjects
AURORA kinases, MULTIPLE myeloma, HISTONES, WESTERN immunoblotting, THROMBOCYTOPENIA, MYELOSUPPRESSION, HEMATOPOIETIC growth factors
Abstract

The article focuses on a research related to study of inhibitor of aurora kinase called AT9283 found in patients with refractory and relapsed multiple myeloma through clinical trials. Topics discussed include measurement of expression of Histone H3 protein by western blot analysis; occurrence of thrombocytopenia in trial patients; and association of administration of AT9283 with myelosuppression; and usage of hematopoietic growth factors to manage myelosuppression.

Published
2016
Full Text
View/download PDF

223. Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant

Author

Villa, Diego, primary, Gubbay, Jonathan, additional, Sutherland, D. Robert, additional, Laister, Robert, additional, McGeer, Allison, additional, Cooper, Curtis, additional, Fortuno, Edgardo S., additional, Xu, Wei, additional, Shi, Lily, additional, Kukreti, Vishal, additional, Crump, Michael, additional, and Kuruvilla, John, additional

Published
2013
Full Text
View/download PDF

234. MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study

Author

Merlini, Giampaolo, primary, Sanchorawala, Vaishali, additional, Zonder, Jeffrey A., additional, Kukreti, Vishal, additional, Schonland, Stefan O, additional, Jaccard, Arnaud, additional, Dispenzieri, Angela, additional, Cohen, Adam D., additional, Berg, Deborah, additional, Liu, Guohui, additional, Bacco, Alessandra Di, additional, Gupta, Neeraj, additional, Hui, Ai-Min, additional, Palladini, Giovanni, additional, and Comenzo, Raymond L., additional

Published
2012
Full Text
View/download PDF

237. Secondary Myelodysplastic Syndrome/Acute Myeloblastic Leukemia During Lenalidomide-Based Regimens in Relapsed and/or Refractory Multiple Myeloma Patients: Single Center Experience

Author

Kotchetkov, Rouslan, primary, Masih-Khan, Esther, additional, Chu, Chia-Min, additional, Trieu, Young, additional, Dean, Saima, additional, Maganti, Manjula, additional, Chen, Christine I., additional, Kukreti, Vishal, additional, Trudel, Suzanne, additional, and Reece, Donna E., additional

Published
2012
Full Text
View/download PDF

238. Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Author

Crump, Michael, primary, Kuruvilla, John, additional, Couban, Stephen, additional, Macdonald, David, additional, Kukreti, Vishal, additional, Kouroukis, C. Tom, additional, Meyer, Ralph M., additional, Rubinger, Morel, additional, Buckstein, Rena, additional, Imrie, Kevin R, additional, Federico, Massimo, additional, Renzo, Nicola Di, additional, Howson-Jan, Kang, additional, Baetz, Tara, additional, Kaizer, Leonard, additional, Voralia, Michael, additional, Olney, Harold J., additional, Turner, A. Robert, additional, Sussman, Jonathan, additional, Hay, Annette E, additional, Djurfeldt, Marina, additional, Chen, Bingshu E, additional, and Shepherd, Lois, additional

Published
2012
Full Text
View/download PDF

240. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Author

Siegel, David S., primary, Martin, Thomas, additional, Wang, Michael, additional, Vij, Ravi, additional, Jakubowiak, Andrzej J., additional, Lonial, Sagar, additional, Trudel, Suzanne, additional, Kukreti, Vishal, additional, Bahlis, Nizar, additional, Alsina, Melissa, additional, Chanan-Khan, Asher, additional, Buadi, Francis, additional, Reu, Frederic J., additional, Somlo, George, additional, Zonder, Jeffrey, additional, Song, Kevin, additional, Stewart, A. Keith, additional, Stadtmauer, Edward, additional, Kunkel, Lori, additional, Wear, Sandra, additional, Wong, Alvin F., additional, Orlowski, Robert Z., additional, and Jagannath, Sundar, additional

Published
2012
Full Text
View/download PDF

242. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Author

Vij, Ravi, primary, Wang, Michael, additional, Kaufman, Jonathan L., additional, Lonial, Sagar, additional, Jakubowiak, Andrzej J., additional, Stewart, A. Keith, additional, Kukreti, Vishal, additional, Jagannath, Sundar, additional, McDonagh, Kevin T., additional, Alsina, Melissa, additional, Bahlis, Nizar J., additional, Reu, Frederic J., additional, Gabrail, Nashat Y., additional, Belch, Andrew, additional, Matous, Jeffrey V., additional, Lee, Peter, additional, Rosen, Peter, additional, Sebag, Michael, additional, Vesole, David H., additional, Kunkel, Lori A., additional, Wear, Sandra M., additional, Wong, Alvin F., additional, Orlowski, Robert Z., additional, and Siegel, David S., additional

Published
2012
Full Text
View/download PDF

245. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

Author

Sanchorawala, Vaishali, Palladini, Giovanni, Kukreti, Vishal, Zonder, Jeffrey A., Cohen, Adam D., Seldin, David C., Dispenzieri, Angela, Jaccard, Arnaud, Schönland, Stefan O., Berg, Deborah, Yang, Huyuan, Gupta, Neeraj, Hui, Ai-Min, Comenzo, Raymond L., and Merlini, Giampaolo

Abstract

This phase 1/2 study assessed the safety, tolerability, and preliminary efficacy of the oral proteasome inhibitor (PI) ixazomib in patients with relapsed/refractory immunoglobulin light chain (AL) amyloidosis. Ixazomib was administered to adult patients with relapsed/refractory AL amyloidosis after 1 or more prior lines of therapy (including bortezomib) on days 1, 8, and 15 of 28-day cycles, for up to 12 cycles. Patients with less than partial response after 3 cycles received oral dexamethasone (40 mg, days 1-4) from cycle 4. A 3+3 dose-escalation phase was followed by 2 expansion cohorts (PI-naive and PI-exposed patients) at the maximum tolerated dose (MTD). Twenty-seven patients were enrolled: 11 during dose escalation (6 at 4.0 mg and 5 at 5.5 mg) and 16 during dose expansion (4.0 mg). Three patients experienced dose-limiting toxicities: 1 at 4.0 mg and 2 at 5.5 mg; the MTD was determined as 4.0 mg. Most common adverse events (AEs) included nausea, skin and subcutaneous tissue disorders (SSTD), diarrhea, and fatigue; grade 3 or higher AEs included dyspnea, fatigue, and SSTD. Overall, the hematologic response rate was 52% in patients treated at the MTD (n = 21). Organ responses were seen in 56% of patients (5 cardiac, 5 renal). Median hematologic progression-free survival was 14.8 months; 1-year progression-free and overall survival rates were 60% and 85%, respectively (median follow-up, 16.9 months). Weekly oral ixazomib appears to be active in patients with relapsed/refractory AL amyloidosis, with a generally manageable safety profile. The study was registered at clinicaltrials.govas #NCT01318902. A phase 3 study is ongoing (#NCT01659658).

Published
2017
Full Text
View/download PDF

247. CYBOR-D Induction Therapy In Clinical Practice

Author

Chen, Christine, primary, Masih-Khan, Esther, additional, Jimenez-Zepeda, Victor, additional, Reece, Donna E., additional, Trudel, Suzanne, additional, Tiedemann, Rodger E., additional, and Kukreti, Vishal, additional

Published
2011
Full Text
View/download PDF

250. Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

Author

Jakubowiak, Andrzej J, primary, Siegel, David S., additional, Singhal, Seema, additional, Martin, Thomas, additional, Lonial, Sagar, additional, Kukreti, Vishal, additional, Bahlis, Nizar, additional, Chanan-Khan, Asher Alban, additional, Alsina, Melissa, additional, Somlo, George, additional, Buadi, Francis K, additional, Reu, Frederic J., additional, Song, Kevin W., additional, Kunkel, Lori, additional, Wear, Sandra M., additional, Wong, Alvin F., additional, Orlowski, Robert Z., additional, Stewart, A. Keith, additional, Jagannath, Sundar, additional, and Wang, Luhua, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results